COMPASS Pathways Past Earnings Performance
Past criteria checks 0/6
COMPASS Pathways's earnings have been declining at an average annual rate of -28.9%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-28.9%
Earnings growth rate
11.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -74.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Nov 01Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Aug 19Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Jul 08Psychedelics Closer To Commercialization; Compass Far And Away The Leader
May 23COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Feb 08Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Dec 06
Booker again pushes for easier access to psychedelics for terminally ill patients
Oct 19Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Aug 13COMPASS Pathways And The Trillion Dollar Opportunity
Aug 11COMPASS Pathways ADS Q2 2022 Earnings Preview
Aug 03COMPASS Pathways names new CEO
Jul 19Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy
Jun 30We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely
Apr 28Checking In On Compass Pathways
Mar 02We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth
Dec 29Compass Pathways: Psychedelics For Mental Health
Nov 23Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy
Sep 17COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
Sep 15Compass Pathways: Huge Growth Potential, But I'm Cautious
Jun 04COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
May 25COMPASS Pathways raises $144M capital via equity offering
Apr 30COMPASS Pathways launches public offering
Apr 27We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate
Feb 08Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront
Jan 01Compass Pathways: Risky And Overvalued
Dec 18What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?
Dec 18Revenue & Expenses Breakdown
How COMPASS Pathways makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -144 | 54 | 100 |
| 30 Jun 24 | 0 | -139 | 52 | 90 |
| 31 Mar 24 | 0 | -129 | 50 | 82 |
| 31 Dec 23 | 0 | -118 | 49 | 75 |
| 30 Sep 23 | 0 | -117 | 51 | 66 |
| 30 Jun 23 | 0 | -102 | 50 | 58 |
| 31 Mar 23 | 0 | -95 | 48 | 53 |
| 31 Dec 22 | 0 | -92 | 45 | 51 |
| 30 Sep 22 | 0 | -86 | 48 | 46 |
| 30 Jun 22 | 0 | -84 | 46 | 45 |
| 31 Mar 22 | 0 | -80 | 43 | 41 |
| 31 Dec 21 | 0 | -72 | 39 | 34 |
| 30 Sep 21 | 0 | -65 | 31 | 27 |
| 30 Jun 21 | 0 | -66 | 28 | 23 |
| 31 Mar 21 | 0 | -64 | 31 | 20 |
| 31 Dec 20 | 0 | -60 | 28 | 19 |
| 30 Sep 20 | 0 | -49 | 24 | 19 |
| 30 Jun 20 | 0 | -38 | 20 | 16 |
| 31 Mar 20 | 0 | -25 | 11 | 13 |
| 31 Dec 19 | 0 | -20 | 9 | 10 |
Quality Earnings: CMPS is currently unprofitable.
Growing Profit Margin: CMPS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CMPS is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare CMPS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CMPS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: CMPS has a negative Return on Equity (-74.77%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 01:22 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
COMPASS Pathways plc is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |